The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

XXVIIIth Canadian Congress of Neurological Sciences
June 16-19, 1993
Toronto, Ontario

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association for Child Neurology

Volume 19, No. 4 November 1992

To a parkinsonian patient, a little help means a lot.

Adding Parlodel to levodopa can improve symptom control. Because you want to help your patient get more out of life's little pleasures.

Add

P PARLODEL®
(bromocriptine mesylate)

Because quality of life is the issue.

SANDOZ PAAB MEMBER PMAC

Sandoz Canada Inc., P.O. Box 385, Dorval, Quebec H9R 4P5

For brief prescribing information see page xx

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

The Canadian Journal of Neurological Sciences

VOLUME 19, NO. 4, NOVEMBER, 1992

Le Journal Canadien des Sciences Neurologiques

Table of Contents

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

The Official Journal of:/La Revue Officielle de:

The Canadian Neurological Society
La Société Canadienne de Neurologie
President/Président — C.W. McCormick
Secretary-Treasurer/Secrétaire-Trésorier — O. Suchowersky

The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie
President/Président — H.J. Hoffman
Secretary-Treasurer/Secrétaire-Trésorier — Renn Holness

The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique
President/Président — Bryan Young
Secretary-Treasurer/Secrétaire-Trésorier — Michael Jones

The Canadian Association for Child Neurology
L'Association Canadienne de Neurologie Pédiatrique
President/Président — Shashi Seshia
Secretary-Treasurer/Secrétaire-Trésorier — William Logan

The permanent secretariat for the 4 societies and the Canadian Congress of Neurological Sciences is at/
Le secrétariat des 4 associations et du Congrès Canadien des Sciences Neurologiques est situe en permanence à:
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is $60 for members; $70 for non-members in Canada; $80 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students $30 per annum (members); $40 per annum (non-members). Single copies $18 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575.

Mailed under Publications Mail registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus, Excerpta Medica and Current Contents — Clinical Practice and Life Sciences.*

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 60 $ pour les membres; 70 $ pour les non-membres au Canada; 80 $ pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 30 $ par année (membres); 40 $ par année (non-membres). Copie simple: 18 $ plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 4220, *Station C, Calgary, AB Canada T2T 5N1. Par courrier: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575.*

Posté sous permis de poste-publications no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus, Excerpta Medica et Current Contents — Clinical Practice et Life Sciences.*

Advertising representative/Représentant de publicité Sally Gregg, Canadian Journal of Neurological Sciences
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7 — (403)-229-9575

Printer/Imprimeur McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671

Pour documentation voir page xxv

For brief prescribing information see page xviii

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

Information for Authors

The Canadian Journal of Neurological Sciences publishes original articles in neurology, neurosurgery and basic neurosciences. Manuscripts are considered for publication with the understanding that they, or the essence of their content, have not been published elsewhere except in abstract form and are not under simultaneous consideration by another journal. Manuscripts should be submitted to:

James A. Sharpe
Editor
Canadian Journal of Neurological Sciences
P.O. Box 4220, Station "C"
Calgary, Alberta
T2T 5N1, Canada

Manuscript Preparation

Submit five high quality copies of the manuscript. Papers will be accepted in English or French. All papers should be accompanied by an abstract of 150 words or less on a separate page; preferably in both languages, although the Journal will provide the translation if required. Submit two original sets and three copies of illustrations. All manuscripts must be double spaced throughout including references and legends for illustrations. Margins of at least 25mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the Journal office, but the main points are summarized here. Articles should be submitted under conventional headings of "introduction", "methods and materials", "results", "discussion", but other headings and subheadings will be considered if more suitable for a particular manuscript.

A title page should identify the title of the article, authors, name of institution(s) from which the work originated and the address, telephone and fax numbers of the corresponding author. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support should be typed on a separate page at the end of the text.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees celsius. English language text may use either British or American spelling, but should be consistent throughout.

After the paper has been reviewed, the corresponding author will be requested to submit four printouts of the revised manuscript and a computer floppy disk ($3^1/_2$" or $5^1/_4$" size) containing the article. Identify clearly on the disk: system - i.e.: MS dos or Macintosh; format - i.e.: saved in ASCII format; software program and version; first author's name printed on the disk.

Review Articles on selected topics are also published by the Journal. They are usually invited, but unsolicited reviews will be considered. It is recommended that authors intending to submit review articles contact the Editor in advance.

Letters to the Editor: Letters concerning matters arising in recent articles are welcome. Letters should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

References

Number references in the order of their citation in the text. Those cited only in tables or in legends for illustrations are numbered according to the sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should include the names of up to five authors; if there are more, cite the first three, then "et al.". Provide the full title, year of publication, volume number and inclusive pagination for journal articles. For any reference cited as "in press", five copies of the article must accompany the author's manuscript. Do not reference unpublished or "submitted" papers; these can be mentioned in the body of the text and authors must provide five copies of "submitted" manuscripts. Avoid "personal communications" and, if necessary, include them in the body of the text, not among the references. Reference citations should not include unpublished presentations or other non-accessible material. Books or chapter references should also include the place of publication and the name of the publisher. Examples of correct forms of reference follow:

Journals

Yang JF, Fung M, Edamura R, et al. H-Reflex modulation during walking in spastic paretic subjects. Can J Neurol Sci 1991; 18: 443-452.

Chapter in a book

McGeer PL, McGeer EG, Amino acid neurotransmitters. *In*: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. Basic Neurochemistry. Boston: Little, Brown & Co., 1981: 233-254.

Illustrations

Submit two original sets of illustrations. Provide three additional sets for reviewers and editors; these may be prints or photocopies depending on the material to be illustrated. We will not return illustrations; therefore, authors should keep negatives for all photographs. Submit high quality glossy black and white photographs perferably 127 x 173 mm (5" x 7"). Original art work and radiographs should not be submitted. The additional cost of coloured illustration must be borne by the authors; quotations are available upon request from the Journal office. Identify each figure with a label at the back indicating top, figure number and first author. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with a scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations.

Tables

Type tables double-spaced on pages separate from the text. Provide a table number and title for each. Particular care should be taken in the preparation of tables to ensure that the data are presented clearly and concisely. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

See page ix

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

Getting more reliable data for more confident evoked potential and electrophysiologic analyses is easy. All you need is the new Nicolet Spirit.™

Reliable. Powerful. Complete.

Spirit gives you data quality like you've never seen before. Signal-to-noise ratio measurements quantify the amount of noise entering your data so waveform reliability is optimized. Powerful digital filtering with on-line and optional off-line functions further enhances the quality of the information.

Collect reliable data over long distances. Spirit makes it possible. Unique digital amplifiers, built into the headbox, minimize electrical interference so information remains accurate—even in a demanding operating room environment.

Easy. Fast. Flexible.

Spirit handles your needs from diagnostic evoked potentials to operating room applications. Its multitasking capabilities, intuitive software, color-coded waveforms and more make operation easy. . .and fast.

Trust a leader in advanced diagnostic instruments to help you diagnose with more confidence. Trust Nicolet. With offices worldwide, we have a Nicolet representative in your area.

Call or write today for further information.

Nicolet Instruments Canada, Inc.
1-1200 Aerowood Drive
Mississauga, Ontario, L4W 2S7
Canada Tel. 416-625-8302
Toll free in Canada 1-800-387-3385

Nicolet
INSTRUMENTS OF DISCOVERY

The Nicolet Spirit.™

It brings new confidence to electrophysiologic analysis.



https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

Low-dose Prolopa. Benefits for the brain and the body.





The newest therapy recommendations for Parkinson's disease are to begin levodopa therapy at the lowest effective dose.

Not all levodopa combinations are formulated to be used at low doses.* For example, the manufacturer of 100 levodopa/25 carbidopa (MSD) recommends the equivalent of 3 tablets per day[1] to reduce the incidence of nausea and vomiting so often associated with early levodopa therapy.[1]

Low-dose Prolopa (50/12.5). A unique levodopa formulation for few G.I. side effects.

Prolopa uses a different peripheral decarboxylase inhibitor.[1] It allows you to start therapy with the lowest recommended levodopa dosage and a low incidence of nausea and vomiting.[2]

Consider initiating with Prolopa. For early Parkinson's control with a lower dose.

PROLOPA® 50/12.5
(levodopa 50 mg / benserazide 12.5 mg)

Levodopa that starts lower.

*Less than 300 mg of levodopa per day

PAAB

For brief prescribing information see page xxiv

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press



https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press



On peut facilement reconnaître le jeune patient épileptique traité au Tegretol® CR.

Excellent contrôle des crises

Tegretol CR (carbamazépine à libération contrôlée) maîtrise les crises chez de nombreux patients, causant peu d'impact sur la fonction cognitive[1,2,3,4]. Contrairement aux médicaments tels la phénytoïne, Tegretol CR permet à de nombreux patients de penser clairement et de donner le meilleur d'eux-mêmes[1,2,3,4].

Taux sanguins uniformes

Tegretol CR cause moins de "hauts et de bas" dans les taux sanguins que le Tegretol conventionnel. Les effets secondaires sont ainsi réduits et le modèle de fonction cognitive est plus stable[5,6].

Posologie b.i.d. commode

Lorsque vous instituez ou remplacez un traitement, pensez au Tegretol CR. Il est présenté en comprimés à 200 mg et 400 mg facilement divisibles pour une plus grande souplesse d'administration et améliorer l'observance du patient.



TEGRETOL® CR.

Aide les épileptiques à réaliser leur plein potentiel.

Gelgy Mississauga, Ontario L5N 2W5

PAAB OCPP MEMBRE ACSM G-92111F

Pour documentation voir pages xxi

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press

For brief prescribing information see page xix

https://doi.org/10.1017/S0317167100041573 Published online by Cambridge University Press